19:25 , Dec 21, 2018 |  BC Week In Review  |  Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). Gilead received exclusive, worldwide rights to AGEN1423, options to bispecific antibody AGEN1223 and...
00:06 , Dec 21, 2018 |  BC Extra  |  Company News

Gilead expands immuno-oncology pipeline with license from Agenus

Gilead Sciences Inc. (NASDAQ:GILD) received rights to a bispecific immuno-oncology molecule and options for two additional immuno-oncology candidates from Agenus Inc. (NASDAQ:AGEN). The deal, Gilead's second of the week, will also extend Agenus’ cash reserves....
00:30 , Nov 15, 2018 |  BC Extra  |  Company News

Management tracks: Ascletis, Agenus

Antiviral company Ascletis Pharma Inc. (HKSE:1672) hired Lindi Tan as CFO. She was a global healthcare analyst at SeaTown Holdings International. Ascletis was the first biotech to go public on the Hong Kong stock exchange's...
20:07 , May 18, 2018 |  BC Week In Review  |  Clinical News

Agenus shifts focus to cervical cancer from first-line NSCLC

Agenus Inc. (NASDAQ:AGEN) said in its 1Q18 earnings report that it shifted its developmental strategy to first seek approval of its checkpoint inhibitors as a second-line treatment for cervical cancer instead of as a first-line...
23:21 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis B virus (HBV) Patient sample and mouse studies suggest agonizing OX40 could help treat HBV infection in patient subsets with poor viral clearance, including pediatric patients with acute infection and adults with chronic...
16:25 , Feb 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lymphoma; breast cancer; colorectal cancer Mouse studies suggest intratumoral injection of a TLR9 agonist and an agonist antibody against OX40 could help treat lymphoma, breast cancer and colorectal cancer. In a mouse model of...
00:38 , Jan 31, 2018 |  BC Extra  |  Company News

Management tracks: Ipsen, Dragonfly

Ipsen Group (Euronext:IPN; Pink:IPSEY) appointed Sotirios Stergiopoulos CMO. He will continue to serve as SVP, head of global medical affairs. Cancer company Dragonfly Therapeutics Inc. (Cambridge, Mass.) hired Jean-Marie Cuillerot as CMO. He was CMO...
18:23 , Jan 12, 2018 |  BC Week In Review  |  Company News

HealthCare Royalty in vaccine royalty deal with Agenus

Agenus Inc. (NASDAQ:AGEN) will sell to HealthCare Royalty Partners (Stamford, Conn.) royalty rights on sales of vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) containing Agenus' QS-21 Stimulon adjuvant. The biotech will receive $190 million in cash,...
22:46 , Jan 8, 2018 |  BC Extra  |  Company News

HealthCare Royalty in deals with Agenus, Albireo

Agenus Inc. (NASDAQ:AGEN) said it will sell to HealthCare Royalty Partners (Stamford, Conn.) royalty rights on sales of vaccines from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) containing Agenus' QS-21 Stimulon adjuvant. The biotech will receive $190 million...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...